OncoMatch/Clinical Trials/NCT05454488
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
Is NCT05454488 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Focal Cryoablation for prostate cancer.
Treatment: Focal Cryoablation — To learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling prostate cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage ≤T2BN0M0
Grade: gg2gg3 (gleason grade group)
Prior therapy
Cannot have received: radiation therapy
Any previous treatment for prostate cancer, including radiation therapy
Cannot have received: hormonal treatment
Any previous treatment for prostate cancer, including ... hormonal treatment
Cannot have received: biologic therapy
Any previous treatment for prostate cancer, including ... biologic therapy for prostate cancer
Cannot have received: chemotherapy
Any previous treatment for prostate cancer, including ... chemotherapy
Cannot have received: prostate outlet procedure (TURP, HoLEP, greenlight, microwave ablation, aquablation, UroLift, simple prostatectomy)
Prior TURP or other prostate outlet procedure such as HoLEP, greenlight, microwave ablation, aquablation, UroLift, or simple prostatectomy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify